We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00260247
Recruitment Status : Completed
First Posted : December 1, 2005
Last Update Posted : April 22, 2015
Danish Research Agency
Information provided by:
Odense University Hospital

Brief Summary:

This is a study of the possible effect of two antiepileptic drug on enzymes in the liver that metabolizes a number of drugs. It is a well know fact that carbamazepine induces some of these enzymes and this may reduce the effect of concomitantly administered drugs. Clinical observations suggest that oxcarbazepine does not induce these enzymes to the same degree.

This study directly compares the ability of these two drugs to induce the cytochrome P450 3A4 enzyme, in healthy volunteers using a well defined biomarker reaction of a specific enzyme activity.

It is the hypothesis that oxcarbazepine induces CYP3A4 to a lesser degree than carbamazepine.

Condition or disease Intervention/treatment Phase
Metabolic Clearance Rate Drug: carbamazepine oxcarbazepine Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Induction of Drug Metabolism: A Comparative, Pharmacokinetic in Vivo Study of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4.
Study Start Date : April 2005
Primary Completion Date : October 2006
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Formation clearance of 3-hydroxyquinidine

Secondary Outcome Measures :
  1. Ratio of metabolite to drug AUC's of 3-OH quinidine to quinidine.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI < 30
  • Non smoker
  • No signs or symptoms of disease by routine laboratory analysis, ECG and physical examination (general appearance assessment; pulmonal and cardiac stetoscopy; abdominal palpation)
  • Informed consent

Exclusion Criteria:

  • signs or symptoms of disease by routine laboratory analysis, ECG and physical examination
  • mental disease
  • participation in another clinical trial involving drugs with 3 months of randomization
  • donation of more than 500 mL blood within 3 months of randomization
  • intake of more than 21 alcohol equivanlents (one normal strength beer contain one alcohol equivalent)per week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00260247

University of Southern Denmark
Odense, Denmark, 5210
Sponsors and Collaborators
Odense University Hospital
Danish Research Agency
Principal Investigator: Per Damkier, MD, Ph.D. Odense University Hospital

ClinicalTrials.gov Identifier: NCT00260247     History of Changes
Other Study ID Numbers: AKF-315
First Posted: December 1, 2005    Key Record Dates
Last Update Posted: April 22, 2015
Last Verified: March 2005

Keywords provided by Odense University Hospital:
In vivo

Additional relevant MeSH terms:
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators